• KOL
    • Rheumatoid Arthritis
    • Piet L C M Van Riel
    • Piet L C M van Riel: Influence Statistics

      Piet  L C M van Riel

      Piet L C M van Riel

      Show email address

      Radboud University Medical Centre, Radboud Institute for Health Sciences, IQ Healthcare, Nijmegen, The Netherlands. | Rheumatology, Radboud University Nijmegen, Nijmegen, The ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Piet L C M van:Expert Impact

      Concepts for whichPiet L C M vanhas direct influence:Rheumatoid arthritis,Patients rheumatoid arthritis,Arthritis rheumatoid,Rheumatoid arthritis patients,Disease activity score,Monoclonal antibodies,Necrosis factor,Systemic sclerosis.

      Piet L C M van:KOL impact

      Concepts related to the work of other authors for whichfor which Piet L C M van has influence:Rheumatoid arthritis,Ankylosing spondylitis,Systemic sclerosis,Autoimmune diseases,Necrosis factor,Radiographic progression,Monoclonal antibodies.

      KOL Resume for Piet L C M van Riel

      Year
      2021

      Radboud University Medical Centre, Radboud Institute for Health Sciences, IQ Healthcare, Nijmegen, The Netherlands.

      Department of Rheumatology, Bernhoven, Uden

      2020

      Department of Rheumatology, Bernhoven, Uden, The Netherlands

      2019

      Department of IQ Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands

      2018

      Rheumatology, Bernhoven, Uden

      IQ Healthcare, Radboud UMC, Nijmegen

      2017

      Bernhoven, Department of Rheumatology, Uden, The Netherlands

      Radboud Institute for Health Sciences, IQ healthcare, Radboud University Medical Center, Nijmegen.

      2016

      Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen; and Department of Rheumatology, Bernhoven, Uden, The Netherlands.

      Rheumatology, Bernhoven Hospital, Uden

      Radboud University Medical Center Nijmegen The Netherlands

      2015

      From the Department of Rheumatology, Radboud University Medical Centre, and the Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands.Y.M.R. de Punder, MD; T.L.Th. A. Jansen, MD, PhD; A.E. van Ede, MD, PhD; P.L.C.M. van Riel, MD, PhD, Professor of Rheumatology; J. Fransen, PhD, Department of Rheumatology, Radboud University Medical Centre; A.A. den Broeder, MD, PhD, Department of Rheumatology, Sint Maartenskliniek.

      Radboud University Medical Center, Radboud Institute for Health Sciences, IQ Healthcare, P.O. Box 9101, 6500, HB, Nijmegen, The Netherlands

      2014

      Radboud Univ Nijmegen Medical Centre, Nijmegen, Netherlands

      Department of Rheumatology, Dudley NHS Hospital Group, Dudley, UK.

      2013

      Radboud Univ Medical Centre, Nijmegen, Netherlands

      Rheumatology

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Piet L C M van Riel is among the top experts in the world.
      Concept World rank
      lef tnfi #1
      monotherapy das28 #1
      daily rheumatoid attitude #1
      drug survival efficacy #1
      activity stopping #1
      treatment 12 areas #1
      ssz naïve patients #1
      mtx das28 score #1
      decision age #1
      haq99 #1
      t2t adherence #1
      cppd synovial fluid #1
      article felson #1
      share esr #1
      eular definition remission #1
      rheumatoid arthritis measures #1
      chemokines scavenger severity #1
      dcs mtp1 #1
      modified 28joint counts #1
      immunosorbent interferon type #1
      increased toxicity combinations #1
      knowledge das28 #1
      infliximab active lef #1
      disease duration modified #1
      interaction disease activity #1
      das28 score baseline #1
      remission 17 weeks #1
      single variables #1
      d2e7 patients #1
      monitor infliximab #1
      subjective outcome disease #1
      esr radiological progression #1
      fatigue communication #1
      interleukin1 statistics tnfalpha #1
      radiologic joint damage #1
      rheumatoid arthritis das28 #1
      mtx vasodilator response #1
      rheumatoid arthritis influence #1
      vivo cxcl4 #1
      das28 measurement #1
      international uniformity variations #1
      das28 disease activity #1
      il18 tlr3 #1
      functional capacity disease #1
      ida ida acd #1
      current health willingness #1
      low level haemoglobin #1
      soluble cxcl16 role #1
      patients thentest #1
      2 increase das28 #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Piet L C M van Riel

      KOL-Index: 21371

      OBJECTIVE: To study the expression of Toll-like receptor 2 (TLR-2) and TLR-4 and its association with proinflammatory cytokines in synovial tissue from patients with rheumatoid arthritis (RA), osteoarthritis (OA), and healthy individuals.

      METHODS: Synovial tissue specimens from 29 RA patients were stained for TLR-2, TLR-4, and proinflammatory cytokines (interleukin-1beta [IL-1beta], IL-12, IL-17, IL-18, and tumor necrosis factor alpha [TNFalpha]). The expression of TLR-2, TLR-4, and ...

      Known for Synovial Tissue | Tlr2 Tlr4 | Proinflammatory Cytokines | Toll‐like Receptors | Patients Rheumatoid Arthritis
      KOL-Index: 18728

      BACKGROUND: Tumour necrosis factor (TNF)-inhibiting therapy increases the risk of serious infections in rheumatoid arthritis (RA). However, it is not clear whether this risk differs between TNF inhibitors.

      OBJECTIVE: To analyse whether the risk of serious infections in patients with RA treated with an anti-TNF inhibitor is different for adalimumab, infliximab and etanercept.

      METHODS: Data from the Dutch RA monitoring registry were used. Incidence rates were calculated from the observed ...

      Known for Risk Infections | Rheumatoid Arthritis | Etanercept Infliximab | Monoclonal Antibodies | 95 Adalimumab
      KOL-Index: 18299

      OBJECTIVE: To validate and compare the definition of the Disease Activity Score 28 based on C-reactive protein (DAS28 (CRP)) to the definition based on erythrocyte sedimentation rate (ESR).

      METHODS: Data were analysed from two randomised, double-blind, placebo-controlled trials of abatacept of 6-month and 12-month duration in patients with rheumatoid arthritis. European League Against Rheumatism (EULAR) response criteria and the proportion of patients in remission (DAS28 <2.6) based on ...

      Known for European League | Rheumatoid Arthritis | Erythrocyte Sedimentation Rate | Response Criteria | Das28 Based
      KOL-Index: 15959

      Physical complaints, such as pain, can be effectively reduced by placebo effects through induction of positive expectations, or increased by nocebo effects through induction of negative expectations. In the present study, verbally induced nocebo and placebo effects on itch were experimentally investigated for the first time. In part 1, the role of verbal suggestions in inducing nocebo effects on itch and pain was investigated. All subjects received the same somatosensory quantitative ...

      Known for Verbal Suggestions | Placebo Effects | Itch Pain | Histamine Application | Induction Nocebo
      KOL-Index: 14922

      OBJECTIVE: To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).

      METHODS: The project followed the EULAR standardised operating procedures, which use a three-step approach: (1) expert-based definition of relevant research questions (November 2006); (2) systematic literature search (November 2006 to May 2007); and (3) expert ...

      Known for Recommendations Disease Activity | Eular Acr | Illness Societies | Relevant Questions | Patients Rheumatoid Arthritis
      KOL-Index: 13919

      OBJECTIVE: To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD treatment has failed.

      METHODS: In a 26 week, double blind, placebo controlled, phase III trial, 544 patients with RA were randomised to monotherapy with adalimumab 20 mg every other week, 20 mg weekly, 40 mg every other week, 40 mg weekly, or placebo. The primary efficacy end point was > or =20% improvement in the ACR core criteria (ACR20 response). Secondary efficacy ...

      Known for Adalimumab Patients | Antirheumatic Drug | Monoclonal Antibodies | Efficacy Safety | Previous Disease
      KOL-Index: 13916

      BACKGROUND: Randomised controlled trials (RCTs) evaluating the efficacy of antagonists to tumour necrosis factor alpha (TNFalpha) showed high response percentages in the groups treated with active drugs.

      OBJECTIVE: To compare the efficacy of anti-TNF treatments for rheumatoid arthritis (RA) patients in RCTs and in daily clinical practice, with an emphasis on the efficacy for patients eligible and not eligible for RCTs of anti-TNF treatments.

      METHODS: First, randomised placebo-controlled ...

      Known for Patients Rcts | Rheumatoid Arthritis | Monoclonal Antibodies | Randomised Controlled Trials | Tnfblocking Agents
      KOL-Index: 13870

      OBJECTIVE: To evaluate the efficacy and safety of etanercept (ETN) monotherapy compared with combination ETN and methotrexate (MTX) treatment in patients with rheumatoid arthritis who had an inadequate response to MTX monotherapy. (The response was defined by the presence of Disease Activity Score-28 joint count (DAS28) >or=3.2 or a combination of >or=5 swollen joints, >or=5 painful joints and erythrocyte sedimentation rate >or=10 mm/h.)

      METHODS: Patients with active rheumatoid arthritis ...

      Known for Rheumatoid Arthritis | Combination Etanercept | Mtx Patients | Inadequate Response | Clinical Signs
      KOL-Index: 13781

      OBJECTIVE: To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).

      METHODS: The project followed the EULAR standardized operating procedures, which use a three-step approach: 1) expert-based definition of relevant research questions (November 2006); 2) systematic literature search (November 2006 to May 2007); and 3) expert consensus ...

      Known for Recommendations Disease Activity | Eular Acr | Relevant Questions | Patients Rheumatoid Arthritis | Rheumatoid Clinical Trials
      KOL-Index: 13490

      OBJECTIVES: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7) in disease modifying antirheumatic drug (DMARD) refractory patients with longstanding, active rheumatoid arthritis (RA).

      METHODS: During a 12 week, double blind, placebo controlled study, 284 patients were randomly allocated to receive weekly subcutaneous injections of adalimumab 20 mg (n = 72), 40 mg (n = 70), or 80 mg (n = 72) or placebo (n = 70) without concomitant DMARDs.

      RESULTS: ...

      Known for Adalimumab Placebo | Monoclonal Antibodies | Rheumatoid Arthritis | 12 Week | Necrosis Factor
      KOL-Index: 13215

      BACKGROUND: Tumour necrosis factor alpha (TNFalpha) neutralising antibody constructs are increasingly being used to treat rheumatoid arthritis (RA).

      OBJECTIVE: To determine potential differences in clinical responses, soluble drug levels and antibody formation between patients with RA receiving infliximab and adalimumab.

      METHODS: 69 patients with RA fulfilling the 1987 American College of Rheumatology criteria and about to start treatment with infliximab or adalimumab, were enrolled ...

      Known for Infliximab Adalimumab | Clinical Responses | Rheumatoid Arthritis | Drug Levels | Monoclonal Antibodies
      KOL-Index: 13177

      BACKGROUND: Dendritic cells orchestrate pivotal immunological processes mediated by the production of cytokines and chemokines.

      OBJECTIVE: To assess whether neutralisation of tumour necrosis factor alpha (TNF alpha) during maturation of dendritic cells affects their phenotype and behaviour, which might explain the beneficial effects of TNF alpha neutralisation in rheumatoid arthritis.

      METHODS: Immature and fully matured dendritic cells were cultured from blood monocytes from patients ...

      Known for Dendritic Cells | Rheumatoid Arthritis | Tnfα Blockade | Cultured Chemokines | Tumor Necrosis Factor

      Key People For Rheumatoid Arthritis

      Top KOLs in the world
      #1
      Paul Emery
      rheumatoid arthritis ankylosing spondylitis radiographic progression
      #2
      Josef Sebastian Smolen
      rheumatoid arthritis systemic lupus erythematosus radiographic progression
      #3
      James F Fries
      rheumatoid arthritis physical function systemic lupus erythematosus
      #4
      John Turner Sharp
      rheumatoid arthritis radiographic progression joint space width
      #5
      Frederick J Wolfe
      rheumatoid arthritis work disability rheumatic diseases
      #6
      Matthew H Liang
      rheumatoid arthritis systemic lupus erythematosus lyme disease

      Radboud University Medical Centre, Radboud Institute for Health Sciences, IQ Healthcare, Nijmegen, The Netherlands. | Rheumatology, Radboud University Nijmegen, Nijmegen, The Netherlands | Department of Rheumatic Diseases, Radboud University Nijmegen

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.